GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
128.18
-1.31 (-1.01%)
At close: Sep 2, 2025, 4:00 PM
127.89
-0.29 (-0.23%)
After-hours: Sep 2, 2025, 6:31 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $102.69M in the quarter ending June 30, 2025, with 45.63% growth. This brings the company's revenue in the last twelve months to $362.32M, up 48.70% year-over-year. In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth.
Revenue (ttm)
$362.32M
Revenue Growth
+48.70%
P/S Ratio
9.87
Revenue / Employee
$362,321
Employees
1,000
Market Cap
3.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
WGS News
- 19 hours ago - Seer Appoints Isaac Ro to its Board of Directors - GlobeNewsWire
- 27 days ago - Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS) - GlobeNewsWire
- 27 days ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth - Seeking Alpha
- 4 weeks ago - WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group - PRNewsWire
- 4 weeks ago - GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 5 weeks ago - GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire